


REMARKS/ARGUMENTS

No new matter is added by the current amendments to the sequence listing. The new Sequence Listing merely corrects errors in the previous Sequence Listing. SEQ ID NOs: 10 and 12 were previously deleted. SEQ ID NOs: 15 and 16 have been amended to indicate the correct positions for Xaa. New sequences 138-161 are added to address each of the permutations of previous SEQ ID NO: 15, which had listed two Xaa as having 0-4 amino acids. A substitute Sequence Listing is submitted herewith.

In light of the foregoing amendments and remarks, the Applicants respectfully request entry of all amendments, withdrawal of all objections and rejections, and allowance of all claims.

Respectfully submitted,



Timothy J. Gaul
Attorney for Applicant
Registration No.: 33,111
Phone: (805) 447-2688
Date: January 19, 2005

Please send all future correspondence to:
US Patent Operations/ TJG
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799